Cancer Research CTRC-AACR San Antonio Breast Cancer Symposium  Tumor Immunology: New Perspectives
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Shin, Y.-K.
Right arrow Articles by Park, J.-G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shin, Y.-K.
Right arrow Articles by Park, J.-G.
[Cancer Research 65, 3162-3170, April 15, 2005]
© 2005 American Association for Cancer Research


Cell and Tumor Biology

Down-regulation of Mitochondrial F1F0-ATP Synthase in Human Colon Cancer Cells with Induced 5-Fluorouracil Resistance

Young-Kyoung Shin1,2, Byong Chul Yoo1, Hee Jin Chang1, Eunkyung Jeon1, Sung-Hye Hong1,2, Mi-Sun Jung1,2, Soo-Jeong Lim1 and Jae-Gahb Park1,2

1 Research Institute and Hospital, National Cancer Center, Goyang, Gyeonggi, Korea and 2 Cancer Research Institute and Cancer Research Center, Seoul National University, Seoul, Korea

Requests for reprints: Jae-Gahb Park, Research Institute and Hospital, National Cancer Center, Goyang, Gyeonggi 411-764, Korea. Phone: 822-760-3380; Fax: 822-742-4727. E-mail: jgpark{at}plaza.snu.ac.kr.

Abstract

5-Fluorouracil (5-FU) is widely used for treatment of advanced colorectal cancer. However, it is common for such patients to develop resistance to 5-FU, and this drug resistance becomes a critical problem for chemotherapy. The mechanisms underlying this resistance are largely unknown. To screen for proteins possibly responsible for 5-FU resistance, cells resistant to 5-FU were derived from human colon cancer cell lines and two-dimensional gel electrophoresis–based comparative proteomics was done. Two-dimensional gel electrophoresis data showed there was lower expression of the {alpha} subunit of mitochondrial F1F0-ATP synthase (ATP synthase) in 5-FU–resistant cells compared with parent cells. Western blotting showed that expression of other ATP synthase complex subunits was also lower in 5-FU–resistant cell lines and that these resistant cells also showed decreased ATP synthase activity and reduced intracellular ATP content. The ATP synthase inhibitor, oligomycin A, strongly antagonized 5-FU–induced suppression of cell proliferation. When 5-FU sensitivity was compared with ATP synthase activity in six different human colon cancer cell lines, a positive correlation has been found. Furthermore, suppressed ATP synthase d-subunit expression by siRNA transfection increased cell viability in the presence of 5-FU. Bioenergetic dysfunction of mitochondria has been reported as a hallmark of many types of cancers (i.e., down-regulation of ATP synthase ß-subunit expression in liver, kidney, colon, squamous oesophageal, and lung carcinomas, as well as in breast and gastric adenocarcinomas). Our findings show that ATP synthase down-regulation may not only be a bioenergetic signature of colorectal carcinomas but may also lead to cellular events responsible for 5-FU resistance.




This article has been cited by other articles:


Home page
Cancer Res.Home page
F. Lopez-Rios, M. Sanchez-Arago, E. Garcia-Garcia, A. D. Ortega, J. R. Berrendero, F. Pozo-Rodriguez, A. Lopez-Encuentra, C. Ballestin, and J. M. Cuezva
Loss of the Mitochondrial Bioenergetic Capacity Underlies the Glucose Avidity of Carcinomas
Cancer Res., October 1, 2007; 67(19): 9013 - 9017.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
S. L. Chi, M. L. Wahl, Y. M. Mowery, S. Shan, S. Mukhopadhyay, S. C. Hilderbrand, D. J. Kenan, B. D. Lipes, C. E. Johnson, M. F. Marusich, et al.
Angiostatin-Like Activity of a Monoclonal Antibody to the Catalytic Subunit of F1F0 ATP Synthase
Cancer Res., May 15, 2007; 67(10): 4716 - 4724.
[Abstract] [Full Text] [PDF]


Home page
Genome ResHome page
A. A. Baran, K. A. Silverman, J. Zeskand, R. Koratkar, A. Palmer, K. McCullen, W. J. Curran Jr, T. B. Edmonston, L. D. Siracusa, and A. M. Buchberg
The modifier of Min 2 (Mom2) locus: Embryonic lethality of a mutation in the Atp5a1 gene suggests a novel mechanism of polyp suppression
Genome Res., May 1, 2007; 17(5): 566 - 576.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
G. Santamaria, M. Martinez-Diez, I. Fabregat, and J. M. Cuezva
Efficient execution of cell death in non-glycolytic cells requires the generation of ROS controlled by the activity of mitochondrial H+-ATP synthase
Carcinogenesis, May 1, 2006; 27(5): 925 - 935.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2005 by the American Association for Cancer Research.